TORONTO, April 27, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for…

Source

Previous articleRed Light Holland and Halo Collective Create Red Light Oregon, Inc. – Forwarding Intentions to Enter Oregon Medicinal Psychedelic Market
Next articleHow To Talk With Your Kids About Psychedelics